RCKT Rocket Pharmaceuticals Inc.

16.45
-1.11  -6%
Previous Close 17.56
Open 17.56
Price To Book 4.67
Market Cap 827261239
Shares 50,289,437
Volume 254,709
Short Ratio
Av. Daily Volume 392,405

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data released January 3, 2017. Primary endpoint not met.
Trabodenoson
Primary open-angle glaucoma (POAG)
Phase 2 trial failed - noted July 7, 2017.
Trabodenoson and latanoprost
Glaucoma
Phase 1 data due 2H 2019.
RP-L201
Leukocyte Adhesion Deficiency-I (LAD-I)
Phase 1 initial data due 2H 2019.
RP-L102
Fanconi Anemia (FA)
Phase 1 trial to commence 2Q 2019 with data due 2020.
RP-A501
Danon disease
Phase 1 trial to commence 2H 2019 with data due 2020.
RP-L301
Pyruvate Kinase Deficiency (PKD)

Latest News

  1. Here’s What Hedge Funds Think About Rocket Pharmaceuticals, Inc. (RCKT)
  2. Rocket Pharmaceuticals: 1Q Earnings Snapshot
  3. Rocket Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights
  4. Rocket Pharmaceuticals Announces Participation at the Bank of America Merrill Lynch 2019 Healthcare Conference
  5. Rocket Pharmaceuticals Presents Preclinical Data of RP-A501 for Danon Disease at the American Society of Gene and Cell Therapy 2019 Annual Meeting
  6. Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine (CIRM)
  7. Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
  8. The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives
  9. Rocket Pharmaceuticals Prices Public Offering of Common Stock
  10. Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
  11. Rocket Pharmaceuticals Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting
  12. Rocket Pharmaceuticals Announces Presentations at the American College of Cardiology 2019 Annual Meeting
  13. Are Insiders Selling Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock?
  14. Rocket Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of RP-L102 in the U.S.
  15. Rocket Pharmaceuticals Sponsors Clinical Trial at University of California, Los Angeles (UCLA)
  16. Rocket Pharmaceuticals Reports Full Year 2018 Financial Results and Operational Highlights
  17. Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
  18. Rocket Pharmaceuticals Recognizes Rare Disease Day® 2019
  19. Rocket Pharmaceuticals Announces Publication of Comprehensive Review of Danon Disease Cases in the International Journal of Cardiology
  20. Rocket Pharmaceuticals Announces Participation in Fireside Chat at the 8th Annual SVB Leerink Global Healthcare Conference